BR112018072883A8 - Sistema de implante subdérmico do agente antiviral 4'-etinil-2-fluoro-2'-desoxiadenosina com polímero eva e seu uso - Google Patents

Sistema de implante subdérmico do agente antiviral 4'-etinil-2-fluoro-2'-desoxiadenosina com polímero eva e seu uso

Info

Publication number
BR112018072883A8
BR112018072883A8 BR112018072883A BR112018072883A BR112018072883A8 BR 112018072883 A8 BR112018072883 A8 BR 112018072883A8 BR 112018072883 A BR112018072883 A BR 112018072883A BR 112018072883 A BR112018072883 A BR 112018072883A BR 112018072883 A8 BR112018072883 A8 BR 112018072883A8
Authority
BR
Brazil
Prior art keywords
deoxyadenosine
ethynyl
fluoro
antiviral agent
implant system
Prior art date
Application number
BR112018072883A
Other languages
English (en)
Other versions
BR112018072883A2 (pt
BR112018072883B1 (pt
Inventor
Elizabeth BARRETT Stephanie
E Gindy Marian
Li Li
S Teller Ryan
P Forster Seth
Original Assignee
Merck Sharp & Dohme
Merck Sharp & Dohme Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme, Merck Sharp & Dohme Llc filed Critical Merck Sharp & Dohme
Publication of BR112018072883A2 publication Critical patent/BR112018072883A2/pt
Publication of BR112018072883A8 publication Critical patent/BR112018072883A8/pt
Publication of BR112018072883B1 publication Critical patent/BR112018072883B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/173—Purine radicals with 2-deoxyribosyl as the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/16—Macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Esta invenção se refere a novos sistemas de liberação de fármaco por implante para liberação de longa atuação de fármacos antivirais. Essas composições são úteis para o tratamento ou prevenção de infecção por vírus da imunodeficiência humana (HIV).
BR112018072883-7A 2016-05-12 2017-05-08 Sistema de implante subdérmico do agente antiviral 4'-etinil-2-fluoro-2'-desoxiadenosina com polímero eva e seu uso BR112018072883B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662335319P 2016-05-12 2016-05-12
US62/335,319 2016-05-12
PCT/US2017/031493 WO2017196697A1 (en) 2016-05-12 2017-05-08 Drug delivery system for the delivery of antiviral agents

Publications (3)

Publication Number Publication Date
BR112018072883A2 BR112018072883A2 (pt) 2019-03-06
BR112018072883A8 true BR112018072883A8 (pt) 2023-01-10
BR112018072883B1 BR112018072883B1 (pt) 2023-01-17

Family

ID=60266868

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018072883-7A BR112018072883B1 (pt) 2016-05-12 2017-05-08 Sistema de implante subdérmico do agente antiviral 4'-etinil-2-fluoro-2'-desoxiadenosina com polímero eva e seu uso

Country Status (11)

Country Link
US (1) US11400186B2 (pt)
EP (1) EP3454868A4 (pt)
JP (1) JP6934019B2 (pt)
KR (1) KR102272235B1 (pt)
CN (2) CN109069526A (pt)
AU (1) AU2017263253B2 (pt)
BR (1) BR112018072883B1 (pt)
CA (1) CA3023364A1 (pt)
MX (1) MX2018013662A (pt)
RU (1) RU2755130C2 (pt)
WO (1) WO2017196697A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20170038B1 (ar) * 2016-02-12 2021-08-17 Merck Sharp & Dohme مركبات للاستخدام لعلاج عدوى بفيروس hiv والوقاية منه
WO2018191093A1 (en) 2017-04-10 2018-10-18 Merck Sharp & Dohme Corp. Drug delivery system for the delivery of antiviral agents
UA128041C2 (uk) 2019-01-25 2024-03-20 Браун Юніверсіті Спосіб лікування пов'язаного з віком запалення у пацієнта
KR20220047307A (ko) * 2019-08-13 2022-04-15 머크 샤프 앤드 돔 코포레이션 항바이러스제의 전달을 위한 약물 전달 시스템
CA3177461A1 (en) * 2020-05-05 2021-11-11 Morgan B. GILES Drug delivery system for the delivery of antiviral agents and contraceptives
WO2023192499A1 (en) * 2022-03-30 2023-10-05 Primefour Therapeutics, Inc. Nucleosides for treating cancer

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8430703D0 (en) * 1984-12-05 1985-01-16 Lrc Products Drug release devices
US5114719A (en) 1987-04-29 1992-05-19 Sabel Bernhard A Extended drug delivery of small, water-soluble molecules
US5601835A (en) 1987-04-29 1997-02-11 Massachusetts Institute Of Technology Polymeric device for controlled drug delivery to the CNS
US4883666A (en) 1987-04-29 1989-11-28 Massachusetts Institute Of Technology Controlled drug delivery system for treatment of neural disorders
US5633000A (en) 1994-06-23 1997-05-27 Axxia Technologies Subcutaneous implant
US5883144A (en) * 1994-09-19 1999-03-16 Sentinel Products Corp. Silane-grafted materials for solid and foam applications
US20040115268A1 (en) * 2000-04-26 2004-06-17 Control Delivery Systems, Inc. Systemic delivery of antiviral agents
EP1503731A1 (en) * 2002-05-07 2005-02-09 Control Delivery Systems, Inc. Processes for forming a drug delivery device
AU2004207523A1 (en) * 2003-01-24 2004-08-12 Control Delivery Systems, Inc. Controlled release of highly soluble agents
TWI336627B (en) * 2003-05-23 2011-02-01 Organon Nv Drug delivery system,and use and manufacturing method thereof
EP1638536A2 (en) * 2003-05-30 2006-03-29 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of nalmefene
TWI434676B (zh) * 2004-03-19 2014-04-21 Merck Sharp & Dohme 可用ｘ射線看出之藥物遞送裝置
CA2502109C (en) 2004-03-24 2010-02-23 Yamasa Corporation 4'-c-substituted-2-haloadenosine derivative
CN100532388C (zh) * 2007-07-16 2009-08-26 郑州大学 2’-氟-4’-取代-核苷类似物、其制备方法及应用
CN102670628B (zh) * 2008-01-25 2015-11-25 奇默里克斯公司 治疗病毒感染的方法
WO2009126293A2 (en) 2008-04-11 2009-10-15 Yale University Potent chimeric nrti-nnrti bifunctional inhibitors of hiv-1 reverse transcriptase
WO2009158415A1 (en) * 2008-06-25 2009-12-30 Endo Pharmaceuticals Solutions Inc. Octreotide implant having a release agent
MY160360A (en) * 2008-12-24 2017-02-28 Janssen Sciences Ireland Uc Implantable devices for treating hiv
EP2547332B1 (en) * 2010-03-16 2018-08-29 Titan Pharmaceuticals, Inc. Heterogeneous implantable devices for drug delivery
US9901563B2 (en) * 2013-03-11 2018-02-27 Delmar Pharmaceuticals, Inc. Compositions to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dianhydrogalactitol and diacetyldianhydrogalactitol
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
RU2015136769A (ru) * 2013-02-05 2017-03-13 Дзе Попьюлейшн Каунсил, Инк. Внутривагинальное кольцо для доставки уникальных комбинаций противомикробных композиций
EP3079659B1 (en) * 2013-12-11 2020-10-28 Merck Sharp & Dohme B.V. Drug delivery system for delivery of anti-virals
WO2016149561A1 (en) * 2015-03-17 2016-09-22 Oak Crest Institute Of Science Subdermal implants for the sustained delivery of water-soluble drugs
WO2017222903A1 (en) 2016-06-20 2017-12-28 Merck Sharp & Dohme Corp. Drug delivery system for the delivery of antiviral agents
EP3515438B1 (en) 2016-09-21 2022-03-02 Merck Sharp & Dohme Corp. Drug delivery system for the delivery of integrase inhibitors
WO2018191093A1 (en) 2017-04-10 2018-10-18 Merck Sharp & Dohme Corp. Drug delivery system for the delivery of antiviral agents

Also Published As

Publication number Publication date
JP2019514992A (ja) 2019-06-06
KR20190005931A (ko) 2019-01-16
EP3454868A4 (en) 2019-12-18
AU2017263253B2 (en) 2022-04-14
CN109069526A (zh) 2018-12-21
CA3023364A1 (en) 2017-11-16
MX2018013662A (es) 2019-03-01
US11400186B2 (en) 2022-08-02
CN115624564A (zh) 2023-01-20
JP6934019B2 (ja) 2021-09-08
RU2755130C2 (ru) 2021-09-13
EP3454868A1 (en) 2019-03-20
US20190388590A1 (en) 2019-12-26
RU2018141823A (ru) 2020-06-15
BR112018072883A2 (pt) 2019-03-06
KR102272235B1 (ko) 2021-07-01
WO2017196697A1 (en) 2017-11-16
AU2017263253A1 (en) 2018-10-25
BR112018072883B1 (pt) 2023-01-17
RU2018141823A3 (pt) 2020-09-10

Similar Documents

Publication Publication Date Title
BR112018072883A8 (pt) Sistema de implante subdérmico do agente antiviral 4'-etinil-2-fluoro-2'-desoxiadenosina com polímero eva e seu uso
PE20151867A1 (es) Polipeptidos f de prefusion del virus sincicial respiratorio (rsv )solubles y estabilizados
BR112018004536A2 (pt) peptídeos de endereçamento à cartilagem
BR112017025108A2 (pt) compostos seletivos de pyy e usos dos mesmos
BR112016016290A2 (pt) Composições farmacêuticas de insulina de ação rápida, conjunto de infusão, sistema de conjunto de infusão e usos de análogos monoméricos ou diméricos de insulina
BRPI0611400A8 (pt) Formulações contendo xiloglicano muco-adesivas úteis em dispositivos médicos e em formulações farmacêuticas
BR112018006817A2 (pt) método de tratamento do câncer
TR201901077T4 (tr) Kanser Veya Enfeksiyon Tedavisine Yönelik Birleşik Preparasyonlar
BR112016022318A2 (pt) método, composição farmacêutica para uso no tratamento de doenças de retina e uso de um anticorpo
CO2019000643A2 (es) Formulaciones gastrorretentivas orales y usos de las mismas
BR112017026294A2 (pt) formulação em gel tópica farmacêutica, e, método para tratar ou prevenir uma doença ou condição.
CO2021006308A2 (es) Proteínas f de prefusión del vrs estabilizadas
NZ740615A (en) A pharmaceutical composition comprising electrohydrodynamically obtained fibres, the composition having improved residence time on the application site
PH12020500076A1 (en) Long-acting formulations
WO2016044839A3 (en) Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
BR112019001131A2 (pt) composto virucida, composição farmacêutica, método de desinfecção e/ou esterilização, dispositivo e uso dos compostos virucidas
UY38386A (es) Sistema de suministro de polímero líquido para la administración prolongada de fármacos
MX2016012319A (es) Formulaciones antihelminticas veterinarias estables.
CO2022001356A2 (es) Sistema de administración de medicamentos para la administración de agentes antivíricos
BR112022010574A2 (pt) Composições farmacêuticas compreendendo cabotegravir
BR112022000971A2 (pt) Derivados de di-hidropirimidina e uso dos mesmos no tratamento de infecção por hbv ou de doenças induzidas por hbv
BR112022021834A2 (pt) Sistema de fornecimento de fármaco por implante, e, método para tratar ou prevenir infecção pelo vírus da imunodeficiência humana e prevenir gravidez
BR112017022390A2 (pt) composição farmacêutica
BR112018002678A2 (pt) composto, composição, e, método para tratar infecção por hiv
BR112019024796A2 (pt) Peptídeos e usos dos mesmos como agentes antivirais

Legal Events

Date Code Title Description
B65X Notification of requirement for priority examination of patent application
B65Y Grant of priority examination of the patent application (request complies with dec. 132/06 of 20061117)
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B25A Requested transfer of rights approved

Owner name: MERCK SHARP AND DOHME LLC (US)

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/05/2017, OBSERVADAS AS CONDICOES LEGAIS